The U.S. Meals and Drug Administration has accepted for Precedence Overview Regeneron Prescribed drugs, Inc.’s REGN supplemental Biologics License Utility (sBLA) for Eylea HD (aflibercept) Injection 8 mg.
The sBLA seeks approval for Eylea HD for macular edema following retinal vein occlusion (RVO) and broadening the dosing schedule to incorporate each 4-week (month-to-month) dosing throughout authorized indications.
The FDA goal motion date is August 19, 2025, following the usage of a Precedence Overview voucher.
Additionally Learn: Vertex, Alnylam Finest Positioned As Biopharma Braces For Tariff Affect, Goldman Sachs Flags Regeneron, Biogen Dangers
Knowledge from the Eylea HD medical program, together with the Section 3 QUASAR trial investigating Eylea HD in RVO, assist the sBLA.
As beforehand presented, QUASAR met its major endpoint at 36 weeks. Eylea HD sufferers have been dosed each 8 weeks (after 3 or 5 month-to-month doses), attaining non-inferior visible acuity features in comparison with these receiving Eylea (aflibercept) Injection 2 mg dosed each 4 weeks.
All anti-VEGF therapies authorized to deal with RVO, together with Eylea, are indicated for month-to-month dosing.
In QUASAR, the protection profile of EYLEA HD (n=591) was much like Eylea (n=301). It remained usually per the identified security profile of Eylea HD in its pivotal trials for authorized indications and with the established security profile of Eylea.
Elevated ocular strain (5%) was the one ocular treatment-emergent opposed occasion that occurred in ≥5% of all Eylea HD sufferers, in comparison with 1.7% of Eylea sufferers.
There was one case every of endophthalmitis and retinal vasculitis in all Eylea HD sufferers, in comparison with two instances of endophthalmitis and no instances of retinal vasculitis in Eylea sufferers.
No instances of occlusive retinal vasculitis have been reported. The speed of intraocular irritation was 0.5% for Eylea HD and 1.3% for Eylea.
The protection and efficacy of Eylea HD for RVO and month-to-month dosing in authorized indications haven’t been evaluated by any regulatory authority.
B of A Securities maintains Regeneron Prescribed drugs with an Underperform and lowers the worth goal from $575 to $547.
Worth Motion: REGN inventory is up 1.3% at $556.48 on the final test Thursday.
Learn Subsequent:
Picture: Gorodenkoff/Shutterstock
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
